Safety and Potential Efficacy of MS-20 In Combination With Pembrolizumab for the Treatment of NSCLC
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
MS-20 was approved as the first oral cancer adjuvant new drug indicated for ameliorating
fatigue and appetite loss associated with cancer chemotherapy via reshaping human gut
ecosystem and restoring immunity. MS-20 has also been shown to be anti-PD-1 booster by
activating tumor-infiltrating lymphocytes (TILs) in mice cancer models, particularly
promoting migration of TILs into tumors and increasing the amount of TILs inside tumors.
Therefore, this study is designed to explore the safety and relationship between gut
microbiome and potential clinical outcomes in NSCLC patients under combination therapy with
pembrolizumab and MS-20.